bah-roo

InvestingWisdom

  • Stop Treating Jim Cramer Like Your Portfolio Manager

    Stop Treating Jim Cramer Like Your Portfolio Manager

    When Jim Cramer says “buy,” Wall Street listens. The real question is: should you? Last week, Cramer called Marvell Technology a buy “going into the quarter.” Days later, Marvell delivered Q4 FY2026 revenue of $2.22B, edging past expectations, with data center revenue up roughly 74% year over year. That’s not a typo. Seventy-four percent. On…

  • If You’re Buying Cramer’s Picks, You’re Probably the Exit Liquidity

    If You’re Buying Cramer’s Picks, You’re Probably the Exit Liquidity

    When Jim Cramer slaps a “buy” on a stock, the real question isn’t whether he likes it. It’s whether you’re early — or you’re the exit ramp. So let’s talk about Marvell (MRVL) and Bausch Health (BHC). Two very different companies. Two very different setups. And two very different levels of risk if you’re chasing…

  • Stop Trading Jim Cramer and Start Picking a Time Horizon

    Stop Trading Jim Cramer and Start Picking a Time Horizon

    Jim Cramer just said buy Marvell and Bausch. The question isn’t what he said — it’s whether you should follow him. Because here’s the dirty secret of 2026 markets: TV calls move stocks for a day. Fundamentals move them for a year. Let’s break this down. Marvell: This One Has Teeth Cramer called Marvell a…

  • Stop Treating Jim Cramer Like Your Portfolio Manager

    Stop Treating Jim Cramer Like Your Portfolio Manager

    Jim Cramer says buy. The stock pops. Retail piles in. Rinse, repeat. But here’s the real question: should you actually follow him into Marvell (MRVL) and Bausch Health (BHC) right now — or is this another case of TV optimism colliding with market reality? Let’s break it down like traders, not fans. Marvell (MRVL): AI…